帕尼培南-倍他米隆在血液科病人合并感染中的应用  

Panipenem/betamipron in treating complicated infection of patients in hematologic department

作　　者：魏征[1] 徐建民[1] 邹善华[1] 程志祥[1] 

机构地区：[1]复旦大学附属中山医院血液科,上海200032

出　　处：《中国新药与临床杂志》2006年第12期962-964,共3页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：目的:观察帕尼培南-倍他米隆在血液科病人合并感染中的治疗效果及安全性。方法:合并感染的血液科病人12例,男性7例,女性5例,年龄(53±s10)a。予帕尼培南-倍他米隆1．0～2．0 g·d-1,静脉滴注,疗程3～10 d。观察临床疗效,随访病原学检查计算清除率,同时在用药前后随访肝、肾功能等评价安全性。结果:致病菌主要包括凝固酶阴性葡萄球菌、肠杆菌、肠球菌以及肺炎克雷伯菌等。治疗有效率为75％,细菌清除率为86％。治疗中未见明显不良反应。结论:帕尼培南-倍他米隆治疗血液科病人合并感染有效且安全。AIM ： To evaluate the efficacy and safety of panipenem/betamipron in treating complicated infection of patients in hematologic department. METHODS： Twelve patients （M 7, F 5, age （53 ± s 10） a） with complicated infections in hematologic department were treated with panipenem/betamipron, 1.0 - 2.0 g·d^-1, iv, gtt, individually for a course of 3 to 10 d. The clinical observation, follow-up pathogenesis testing clearance rate together with hepatic and renal function changes were performed before an after the treatment to assess the efficacy and saffety. RESULTS： Pathogens including coagulase-negative Staphylococcus, Streptococcus viridans, Bacillus coli, Enterococcus and Klebsiella were isolated and confirmed with overall efficacy rate 75 % and the bacteria elimination rate 86 %. No serious adverse reactions occurred during the period of treatment. CONCLUSION： Panipenem/betamipron is efficacious and safe in treating complicated infection for patients in hematologic department.

关 键 词：感染 血液病 帕尼培南 倍他米隆 

分 类 号：R978[医药卫生—药品]